The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

• Published in: Cell reports (Cambridge) Vol. 20; no. 4; pp. 854 - 867
• Main Authors: Zingg, Daniel, Arenas-Ramirez, Natalia, Sahin, Dilara, Rosalia, Rodney A., Antunes, Ana T., Haeusel, Jessica, Sommer, Lukas, Boyman, Onur
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 25.07.2017; Elsevier
• Subjects: Animals; anti-CTLA-4; anti-PD-1; Blotting, Western; Cell Line; Chromatin Immunoprecipitation; CTLA-4 Antigen - metabolism; Enhancer of Zeste Homolog 2 Protein - genetics; Enhancer of Zeste Homolog 2 Protein - metabolism; Enzyme-Linked Immunosorbent Assay; epigenetics; EZH2; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; IL-2 complexes; Immunotherapy; Interleukin-2 - metabolism; melanoma; Melanoma - metabolism; Melanoma - therapy; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; PRC2; T-Lymphocytes - metabolism; tumor immune escape; Tumor Necrosis Factor-alpha - metabolism; tumor resistance; tumor resistance; PRC2; immunotherapy; melanoma; tumor immune escape; anti-CTLA-4; anti-PD-1; IL-2 complexes; epigenetics; EZH2

Immunotherapy and particularly immune checkpoint inhibitors have resulted in remarkable clinical responses in patients with immunogenic tumors, although most cancers develop resistance to immunotherapy. The molecular mechanisms of tumor resistance to immunotherapy remain poorly understood. We now sh...